[Safety and high immunogenicity for children 3 to 15 of a mono- and a divaccine from recombinant influenza A/Brazil /11/78 (H1N1) and A/Bangkok/1/79 (H3N2) viruses obtained from a special donor attenuation base--the cold-adapted virus A/Leningrad/134/47/57 (H2N2)].

: The data on complete safety and high immunogenic potency of intranasal live influenza vaccine from the recombinant A/Brazil/11/78 (H1N1) and A/Bangkok/1/79 (H3N2) strains prepared with a special donor of attenuation, a cold-adapted A/Leningrad/134/47/57 (H2N2) virus, have been obtained. The possibility of using a bivaccine from the recombinant strains constructed on the basis of a single donor of attenuation and inheriting from it most of the genes coding for nonglycosylated proteins was demonstrated. Administration of this bivaccine to children was not accompanied by any increase in the rate of postvaccination febrile reactions, but produced in the vaccinees an intensive immune response to the antigenic components of the vaccine which was in agreement with the data obtained after separate administration of monovaccines.